Difference between revisions of "Belinostat (Beleodaq)"
Jump to navigation
Jump to search
(FDA approval) |
m |
||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *7/3/2014: [http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm403929.htm FDA accelerated approval] "for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)." | + | *7/3/2014: [http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm403929.htm FDA accelerated approval] "for the treatment of patients with relapsed or refractory [[T-cell lymphoma | peripheral T-cell lymphoma (PTCL)]]." |
==Also known as== | ==Also known as== | ||
Revision as of 03:31, 6 November 2014
General information
Class/mechanism: Histone deacetylase (HDAC) inhibitor. Belinostat causes cell cycle arrest and/or apoptosis of tumor cells by blocking HDAC, which results in accumulation of acetylated histones and other proteins.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Patient information may be found in the Belinostat (Beleodaq) package insert.[1]
- Belinostat (Beleodaq) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/3/2014: FDA accelerated approval "for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)."
Also known as
PXD101